The honest way to write about SS-31 dosing is to start with what it is not: there is no approved dose for the things most people are searching for — longevity, energy, recovery, general “mitochondrial support.” Elamipretide (SS-31, formerly MTP-131/Bendavia) is investigational for nearly everything, and its one approval is narrow. The SS-31 evidence review covers the cardiolipin mechanism and the mostly disappointing clinical record. The numbers below describe the doses used in human trials for specific diseases and should never be used as a personal protocol.
The dose the modern trials used: 40 mg/day, subcutaneous
Across elamipretide’s later human trials, the regimen was remarkably consistent: 40 mg once daily, injected subcutaneously. The pivotal Phase 3 trial in primary mitochondrial myopathy, MMPOWER-3, randomized 218 adults to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks — and the drug did not beat placebo on the 6-minute walk test or fatigue.[1] The same 40 mg/day subcutaneous dose was used in the Barth-syndrome crossover trial (TAZPOWER)[3] and in the dry-AMD ReCLAIM study.[5] So when a study or a supplier references “the clinical dose,” this is almost always the number they mean.
Where 40 mg came from: the intravenous dose-escalation study
The 40 mg/day figure was not arbitrary. Before the subcutaneous trials, a Phase 1/2 randomized dose-escalation study tested elamipretide as a two-hour intravenous infusion at 0.01, 0.1 and 0.25 mg/kg/hour in adults with primary mitochondrial myopathy.[2] Only the highest infusion rate produced a walk-distance signal — participants on it walked about 64.5 m farther by day 5, versus 20.4 m on placebo (p = 0.053) — and that signal is what justified moving to a standing daily subcutaneous dose in the larger trials.[2] It is worth noting the original human dosing was intravenous, not the subcutaneous self-injection that gray-market sellers imply, and the pivotal signal it was built on sat right at the edge of statistical significance.
Barth syndrome: the same dose, and the one approval
In the ultra-rare Barth syndrome, TAZPOWER used 40 mg/day subcutaneous elamipretide against placebo in a 12-week crossover; the blinded portion missed its primary endpoints, but the open-label extension — patients continuing the same daily dose out to about 168 weeks — showed sustained gains in muscle strength and cardiac measures.[3][4] On that basis the FDA granted accelerated approval to elamipretide, brand name FORZINITY, in September 2025 — given as a once-daily subcutaneous injection for patients with Barth syndrome weighing at least 30 kg, with a confirmatory trial still required.[6] This is the only context in which elamipretide has an approved dose, and it says nothing about dosing for any other condition.
Dry AMD and heart failure: still investigational
In dry age-related macular degeneration, the small Phase 1 ReCLAIM program also used 40 mg/day subcutaneous elamipretide, reporting mainly that daily self-injection was feasible and tolerable — an early-phase safety-and-feasibility read, not an efficacy dose.[5] Heart-failure work used single infusions rather than a chronic daily dose. None of this establishes a dose for general or preventive use; these were disease trials with disease endpoints.
The honest bottom line
If you compress it to what the evidence supports: elamipretide was studied at 40 mg once daily, subcutaneously, a dose derived from an intravenous escalation study and carried through the myopathy, Barth, and dry-AMD trials — where it mostly failed to beat placebo, with the lone win being a narrow, confirmation-pending Barth-syndrome approval.[1][2][6] There is no established dose for healthy people, no evidence it slows aging, and the real-world product is unregulated and injectable. This is not a self-dosing guide. Any legitimate use runs through a clinician and the FORZINITY approval — not a forum protocol. For the mechanism and full trial record see the SS-31 evidence monograph, and for how other mitochondrial peptides are dosed and evidenced, compare MOTS-c dosage and the humanin evidence review.